ERBB2 and lung carcinoma: Dactinib irreversibly inhibits EGFR and is the first-line treatment for patients with EGFR mutation-positive advanced lung cancer, with activity against all 3 kinase-active ErbB family members (EGFR/HER-1, HER-2, and HER-4).